{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:13:46Z","timestamp":1786119226718,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3,25]]},"DOI":"10.1097\/wnr.0b013e32832984d6","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T16:01:06Z","timestamp":1242921666000},"page":"482-486","source":"Crossref","is-referenced-by-count":10,"title":["Striatal extracellular dopamine levels and behavioural reversal in MPTP-lesioned mice"],"prefix":"10.1097","volume":"20","author":[{"given":"Jeppe","family":"Kirchhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"M\u00f8rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise T.","family":"Brennum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas N.","family":"Sager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210201","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/00023210-200317100-00004","article-title":"Neuroprotective strategies in Parkinson's disease: an update on progress","volume":"17","author":"Mandel","year":"2003","journal-title":"CNS Drugs"},{"key":"R2-6-20210201","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00726-005-0162-4","article-title":"Peculiarities of L-DOPA treatment of Parkinson's disease","volume":"28","author":"Kostrzewa","year":"2005","journal-title":"Amino Acids"},{"key":"R3-6-20210201","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/35072550","article-title":"Experimental models of Parkinson's disease","volume":"2","author":"Beal","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"R4-6-20210201","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0006-8993(87)90033-3","article-title":"Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice","volume":"402","author":"Willis","year":"1987","journal-title":"Brain Res"},{"key":"R5-6-20210201","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/mds.21010","article-title":"Behavioral models of Parkinson's disease in rodents: a new look at an old problem","volume":"21","author":"Meredith","year":"2006","journal-title":"Mov Disord"},{"key":"R6-6-20210201","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0165-0270(02)00360-6","article-title":"Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism","volume":"123","author":"Tillerson","year":"2003","journal-title":"J Neurosci Methods"},{"key":"R7-6-20210201","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1006\/exnr.2002.8021","article-title":"Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"178","author":"Tillerson","year":"2002","journal-title":"Exp Neurol"},{"key":"R8-6-20210201","first-page":"435","article-title":"A simple quantitative bradykinesia test in MPTP-treated mice","volume":"50","author":"Ogawa","year":"1985","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"R9-6-20210201","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0165-0270(98)00078-8","article-title":"The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism","volume":"83","author":"Rozas","year":"1998","journal-title":"J Neurosci Methods"},{"key":"R11-6-20210201","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0014-2999(86)90656-4","article-title":"Some atypical neuroleptics inhibit [3H]SCH 23390 binding in vivo","volume":"120","author":"Andersen","year":"1986","journal-title":"Eur J Pharmacol"},{"key":"R12-6-20210201","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R13-6-20210201","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","article-title":"Measurement of protein using bicinchoninic acid","volume":"150","author":"Smith","year":"1985","journal-title":"Anal Biochem"},{"key":"R14-6-20210201","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1523\/JNEUROSCI.3465-08.2008","article-title":"Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis","volume":"28","author":"Boulet","year":"2008","journal-title":"J Neurosci"},{"key":"R15-6-20210201","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0306-4522(99)00437-6","article-title":"Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment","volume":"95","author":"Elsworth","year":"2000","journal-title":"Neuroscience"},{"issue":"3","key":"R16-6-20210201","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1002\/mds.22062","article-title":"Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease","volume":"23","author":"Obeso","year":"2008","journal-title":"Mov Disord"},{"key":"R17-6-20210201","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0006-8993(99)01209-3","article-title":"Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP","volume":"824","author":"Tanji","year":"1999","journal-title":"Brain Res"},{"key":"R18-6-20210201","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1046\/j.1471-4159.2001.00619.x","article-title":"Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum","volume":"79","author":"Ishiwata","year":"2001","journal-title":"J Neurochem"}],"container-title":["NeuroReport"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001756-200903250-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:49:59Z","timestamp":1786038599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001756-200903250-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,25]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/wnr.0b013e32832984d6","relation":{},"ISSN":["0959-4965"],"issn-type":[{"value":"0959-4965","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3,25]]}}}